BioCentury | Oct 17, 2020
Emerging Company Profile

Fed Bio: designing gut microbiomes with staying power and enhancing immune-modulating bacteria

Fed Bio seeks to eliminate the need for repeated dosing of microbiome therapies for chronic diseases by designing complex bacterial communities that can stably colonize the gut. The biotech, which emerged...
BioCentury | Oct 8, 2020

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

...Details were not disclosed.That same month Genor completed its series B, bringing in new investors Temasek, CR-CP...
BioCentury | Sep 17, 2020

Awaiting dialogue with FDA on GI program, microbiome play Finch looks to autism, HBV with new $90M round

With one pivotal readout in Clostridium difficile already achieved, microbiome company Finch has tapped investors for a $90 million series D round that will fund additional programs, and potentially help...
BioCentury | Aug 26, 2020

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...sisunatovir and bring its N-protein replication inhibitor to the clinic, both to treat respiratory syncytial virus (RSV). CR-CP...
BioCentury | Aug 11, 2020
Product Development

Phase II learnings set up microbiome play Seres for Phase III success

Seres parlayed lessons learned from the failed Phase II trial of SER-109 to treat recurrent C. difficile infection into a Phase III win through improved patient selection and higher dosing. Seres Therapeutics Inc. (NASDAQ:MCRB) added...
BioCentury | Jun 19, 2020
Product Development

Finch’s microbiome therapy clears bar in pivotal C. diff readout

A pivotal Phase II readout for Finch’s microbiome treatment for recurrent Clostridium difficile infection paves the way for a Phase III trial that will further test the therapy in a broad population for which the...
BioCentury | Jun 10, 2020

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...billion takeout of Celgene Corp. CPE and Mirae Asset co-led the round with participation from CR-CP...
BioCentury | Jun 2, 2020

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

...a $160 million series B round led by existing investor Hillhouse Capital. New investors Temasek, CR-CP...
BioCentury | Apr 9, 2020
Product Development

Pfizer’s COVID-19 push: antiviral candidate identified as anti-inflammatory Xeljanz starts trial

...Mpro) - Coronavirus 3C-like proteinase JAK - Janus kinase Sandi Wong, Assistant Editor Jaquinus, Xeljanz, tofacitinib (CP-690,550, CP-690550...
BioCentury | Feb 27, 2020
Product Development

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

...receptor 2 Elizabeth S. Eaton and Hongjiang Li, Staff Writers Cyramza, ramucirumab (IMC-1121B, LY3009806) Tarceva, erlotinib (R1415, RG115, CP-358,774...
Items per page:
1 - 10 of 485